|

AU-011 Clinical Trials

2 actively recruiting trials across 2 locations

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • Aura Biosciences2

Indications

  • Cancer2
  • Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG1
  • Non-Muscle Invasive Bladder Carcinoma1
  • NMIBC1
  • Eye Cancer1

Little Rock, Arkansas1 trial

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Arkansas Urology

Phase 1

Palo Alto, California1 trial

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Byers Eye Institute at Stanford University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.